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Chapter 1
                                    
Introduction
                                      INTRODUCTION
One of the Prime motives of a medicinal chemist is service to medicine Medicinal
chemists  may have  been  stimulated  by  the  need  of  the  sick  for  drugs.  By contributing
therapeutic agents, medicinal chemists have made possible, some of the proudest and most
spectacular achievements of human and veterinary medicine.
The  discovery of  the  medicinal  usefulness  of  a  compound  has  always  stimulated
inquiry  in  to  the  chemical  reactions  and  improved  methods  of  preparation  of  similar
substances.   This  introduces  new dimension  in  the  field  of  synthetic  chemistry like  any
artistic and creative activity1.
Medicinal chemistry is an interdisciplinary science.  It has been stated that ‘Medicinal
Chemistry concerns the discovery, the development, identification and interpretation of the
mode of action of biologically active compounds at the molecular level.  Evidently it touches
all branches of chemistry and biology2. 
The biological direction has added the roles of enzymologist and molecular biologist
to  the group of  research scientists  working under  a  medicinal  chemical  designation.  The
physiochemical direction has required that a quantum mechanician, Spectroscopist, and bio-
pharmacist  be  included.  Attempts  to  correlate  or  reconcile  the  results  of  bio-chemical
measurements  with  physiochemical  calculations  also  occupy  the  attention  of  medicinal
chemists2.
Medicinal  chemistry,  according to Burger,  tries to be based on the ever-increasing
hope that biochemical rationales for drug discovery may be found. In contrast, he described
pharmaceutical  chemistry  with  modification  of  structures  having  known  physiologic  or
pharmacologic effect and with analysis of drugs3.
CANCER:
Normal cells in our body follow an orderly path of growth, division and death. Cancer
is a class of diseases characterized by out-of-control cell growth which harms the body by
forming lumps or masses of tissue called tumors. Tumors are invasive, aggressive and mostly
metastatic. Tumors that stay in one spot and show limited growth are called benign which can
often be removed, and, in most cases, they do not come back. Also, cells in benign tumors do
not spread to other parts of the body. Cancer is, thus, the result of cells that uncontrollably
grow and do not die.                                     
                                  Fig 2. Pathology of cancer
CAUSES OF CANCER
 Exposure to carcinogens
 Ionising  radiations
 Infections 
 Hormonal imbalances
 Immune system dysfunction
 Heredity
TYPES OF CANCER
• Carcinoma - cancer of the skin or  tissues that line or cover internal organs
• Sarcoma -  cancer that starts in bone, cartilage, fat, muscle, blood vessels, or other
connective or supportive tissue
• Leukemia - cancer that starts in blood-forming tissue such as the bone marrow 
• Lymphoma and myeloma - cancers that begin in the cells of the immune system
• Central nervous system cancers - cancers that begin in the tissues of the brain and
spinal cord
• Adenoma - cancers that arise in the thyroid, the pituitary gland, the adrenal gland,
and other glandular tissues
TREATMENT 
 Surgery
 Radiation therapy
 Immunotherapy
 Hormone therapy
 Gene therapy
 Chemotherapy 
CANCER CHEMOTHERAPY
Chemotherapy refers to the treatment of an ailment by chemicals especially by killing
micro-organisms or cancerous cells. Anti neo plastic drugs are used in cancer chemotherapy.
A single "cure" for cancer has proved elusive since there is not a single type of cancer but
more than hundred different  types of  cancer.  Though the available anticancer drugs have
distinct mechanisms of action which may vary in their effects on different types of normal
and cancer cells,  their toxicity to normal rapidly growing cells in the intestinal and bone
marrow areas and the problem of resistance pose a great  problem. For this reason cancer
chemotherapy may consist of using a combination of several drugs for varying lengths of
time.
Categories of Chemotherapy Drugs
Based on their mechanism of action, chemotherapy agents can be divided into three main 
categories as follows:
• Drugs that stop the synthesis of DNA building blocks
 DNA building blocks are folic acid, heterocyclic bases, nucleotides etc. The agents 
that work to block some step in the formation of these building blocks come under 
this category. Examples of drugs in this class include methotrexate, fluorouracil, 
hydroxyurea, mercaptopurine etc.
• Drugs that directly damage the DNA 
These agents chemically damage DNA and RNA by disrupting replication of the DNA
or by the manufacture of nonsense DNA or RNA. Examples of drugs in this class 
include cisplatin, antibiotics – daunorubicin, doxorubicin, etoposide etc.
• Drugs that affect the synthesis or breakdown of the mitotic spindles
These drugs disrupt the formation of these spindles and therefore interrupt cell 
division. Examples of drugs in this class include mitotic disrupters such as 
Vinblastine, Vincristine, Paclitaxel etc.
                      
                  Fig 3. Mechanism of action of some anticancer drugs
ANTIOXIDANT
             The adverse effects of oxidative stress on human health have become a serious issue.
The World Health Organization (WHO)  has estimated that 80% of the earth’s inhabitants rely
on traditional medicine for their primary health care needs, and most of this therapy involves
the use of plant extracts and their active components. Under stress, our bodies produce more
reactive  oxygen  species  (ROS)  (e.g.,  superoxide  anion  radicals,  hydroxyl  radicals  and
hydrogen  peroxide)  than  enzymatic  antioxidants  (e.g.,  superoxide  dismutase
(SOD),glutathione  peroxidase  (GPx),  and  catalase)and  non-enzymatic  antioxidants
(e.g.,ascorbic   acid  (vitamin  C),  tocopherol  (vitamin  E),  glutathione,  carotenoids,  and
flavonoids).  This  imbalance  leads  to  cell  damage  and  health   problems.  A  lack  of
antioxidants,  which  can  quench  the  reactive  free  radicals,  facilitates  the  development  of
degenerative  diseases,  including  cardiovascular  diseases,  cancers,  neurodegenerative
diseases, Alzheimer’s disease and inflammatory diseases. One solution to this problem is to
supplement the diet with antioxidant compounds that are contained in natural plant sources.
These natural plant antioxidants can therefore serve as a type of preventive medicine. Recent
reports indicate that there is an inverse relationship between the dietary intake of antioxidant-
rich foods and the incidence of  human disease.  However,  synthetic  antioxidants,  such as
butylated  hydroxyl toluene (BHT) and butylated hydroxyl anisole  (BHA), have been widely
used  as  antioxidants  in  the  food  industry and  may be  responsible  for  liver  damage and
carcinogenesis.
Antioxidants,  including  phenolic  compounds  (e.g.,  flavonoids,  phenolic  acids  and
tannis), have diverse biological effects, such as anti-inflammatory, anti-carcinogenic and anti
atherosclerotic effects, as a result of their antioxidant activity.
An antioxidant is a molecule capable of inhibiting the oxidation of other molecules.
Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing
agent. Oxidation reactions can produce free radicals.  In turn, these radicals can start chain
reactions that damage cells. Antioxidants terminate these chain reactions by removing free
radical intermediates, and inhibit other oxidation reactions. They do this by being oxidized
themselves, so antioxidants are often reducing agents such as thiols, ascorbic acid or poly
phenols.
        Although oxidation reactions are crucial for life, they can also be damaging; hence,
plants  and  animals  maintain  complex  systems  of  multiple  types  of  antioxidants,  such  as
glutathione,  vitamin  C,  and  vitamin  E  as  well  as  enzymes  such  as  catalase,  superoxide
dismutase  and  various  peroxidases.  Low  levels  of  antioxidants,  or  inhibition  of  the
antioxidant enzymes, cause oxidative stress and may damage or kill cells.
           As oxidative stress might be an important part of many human diseases, the use of
antioxidants in pharmacology is intensively studied, particularly as treatments for stroke and
neurodegenerative diseases. However, it is unknown whether oxidative stress is the cause or
the consequence of disease.
           Reactive oxygen species (ROS). Capable of  causing damage to DNA, has been
associated  with  carcinogenesis,  coronary  heart  disease,  and  many other  health  problems
related to advancing age4. In low concentrations, synthetic antioxidants are also in use for
many  industrial  processes  e.g.  inhibition  of  radical  formation  for  preventing  premature
polymerization during processing, storage and transportation of unsaturated monomers. They
exert their effects by scavenging or preventing the generation of ROS5 which can protect the
formation of free radicals and retard the progress of many chronic diseases including cancer,
neurodegenerative, inflammation and cardiovascular diseases6,7
Heterocyclic compounds:
            Heterocyclic rings, which have been reason for the activity of most of the drugs of
natural  origin leads  to the discovery of many synthetic  drugs possessing the heterocyclic
rings and their fused analogs represent an important class of heterocyclic compounds exists in
numerous  natural  products  displaying  a  wide  range  of  biological  and  pharmaceutical
activities.  On  intensive  research  heterocyclic  derivaties  continue  to  yield  new medicinal
agents8.
Quinazoline:
Quinazoline is a bicyclic compound consisting of a pyrimidine system fused at 5, 6
with benzene ring having broad spectrum of medicinal values. It is a compound made up of
two fused six membered simple aromatic rings, benzene and a pyrimidine ring with keto
group  at  4th  position.  Its  chemical  formula  is  C8H4N2O.  It  is  a  yellow  and  crystalline
compound.  Any  derivative  of  it  may  be  described  as  Quinazolinone  compound.  4(3H)-
Quinazolinone  with  3-substitution  and  various  substituted  phenyl  ring  moieties,  bridged
phenyl rings, heterocyclic rings and aliphatic systems were reported to possess antimicrobial
properties.
Quinazoline ring is a versatile lead molecule which has been investigated widely in
medicinal chemistry due to its important pharmacological activities. These involve analgesic9,
anti-inflammatory10, antihypertensive11, sedative and hypnotic12, antihistaminic13, antitumor14,
antimicrobial, anticonvulsant15, enzyme inhibition activity16 and many other activities.
The new and improved methods for the construction of the 4(3H)-Quinazolinone and
Quinazoline skeletons with a particular emphasis on the 2-substitued and 2,4-disubstituted
analogues.
Quinazolin-4(3H)-one is  4  oxo-1,3-bezopyrimidine  and  the  detailed  chemistry are
discussed in textbook of heterocyclic chemistry.
                                                   
From  literature  review  it  is  known  that  most  of  the  Quinazolin-4(3H)--ones  having
substitution at C-2 and N-3 positions, posses anti microbial activity.
4(3H)-Quinazolinones  and  their  derivatives  constitute  an  important  class  of
heterocyclic  compounds.  They  occupy  an  important  position  in  medicinal  chemistry,
presenting a wide range of bioactivities. Many of them display anti-microbial, anti-tubercular,
anticancer,  anti-HIV,  anti-fungal,  anti-inflammatory,  anticonvulsant,  antidepressant,
hypolipidemic, antiulcer and analgesic or immunotropic activities and are also known to act
as  thymidylate  synthase,  poly  (ADP-ribose)  polymerase  (PARP)  protein  tyrosine  Kinase
inhibitors and dihydrofolate reductase inhibitors.  As pesticides, they are used as insecticides,
fungicides and antiviral agents such as TMV, CMV inhibitors. It is found in many bioactive
natural products and looking at the biological significance of Quinazolinone nucleus it was
thought to design and synthesize new derivatives of it.  
Quinazolin-4(3H)-one  constitute  a  unique  group  of  compound  due  to  the  simultaneous
presence of three characteristic feature 
• Enormous synthetic possibilities are offered by the presence of acetanthranils, often
serve as starting material for more complex compounds via cyclization, condensation
etc.,
• Stability of the nucleus and Wide range of biological activity
The  synthesis  of  both  Quinazolinones  and  Quinazolines  will  be  classified  into  five
categories, based on the substitution patterns of the ring system.
• 3-Substituted-4(3H)-Quinazolinones
• 4-substituted Quinazolines
• 2,3-disubstituted-4(3H)-Quinazolinones
• 2,4-disubtituted-4(3H)-Quinazolinones and Quinazolines
• Many of this 2, 3-disubstituted derivatives are of material importance.
Combinatorial Approaches to Quinazolinones
2,3-disubstituted  Quinazolinones  can  be  synthesized  via  benzoxazinones  and
benzoxadiones.
The  intermediate  (4H)-3,  1-benzoxazinones  were  reacted  with  amino  substituted
compound  and get the desired product.
Using Quinazolinones it would be possible to introduce a variety of substitution in the
core structure in the areas shown in figure. It would be possible to alter the length and nature
of the 2-alkyl chain (R1),  change the functionality at the 3-position (R2) and to introduce
substitution into the carbocyclic ring (R3).
Fig: 1.1 Structural areas of Quinazolinones that can be altered for SAR
study.
These alterations could be achieved individually or in combination and their effects
assessed within biological assays. This structure activity relationship (SAR) study would thus
provide  a  number  of  new  molecules  that  can  be  assayed  for  their  immune  modulatory
properties. It was also intended to use the Quinazolinone structure as a surrogate structure,
expecting  that  alterations  will  mimic  the  relative  equivalents  in  the  original  4-quinolone
system. An example of this would be observing the effect of altering the length of the side
chain and seeing if the activity rises or falls. It would be of interest to see if the change in
activity  parallels  the  4-quinolone  analogues.  A  number  of  Quinazolinones  of  varying
complexity in structure have been reported to have a range of medicinal properties.
For example, Methaqualone  1.2  has sedative effects,  2-alkyl/aryl-3- arylhydrazino-
4(3H)-Quinazolinones  1.3  possess antibacterial  activity,  as well  as central nervous system
(CNS) effects similar to that of monoamine oxidase inhibitors.
                                                                    
Derivatives  of  2,  3-dihydro-2-(aryl)-Quinazolinone  (DHQZ)  1.4  show  some  anti-
tumor  effects  and  various  2-methyl  Quinazolinone  analogues  have  been  synthesized  that
possess anti-folate properties17.
                                                              
                                                          
Many derivatives  of  Quinazoline  system known so  far,  keto-Quinazolines  also  called  as
Quinazolinones, are the most important compounds. Depending upon the position of the keto
or oxo group, these compounds may be classified into two types: 2-(1H) Quinazolinones (or)
1,2-dihydro-2-oxo Quinazolines  and 4(3H)-Quinazolines or 3,4-dihydro-oxoquinazolines .
These systems exhibit lactam-lactam tautomerism and undergo hydroxy group replacement
reactions.  2-Cyano-4(3H)-Quinazolinone  was  the  first  Quinazolinone  derivative  to  be
synthesized.
2. Brief Account of reactivity of 4(3H)-Quinazolinones:
Reactions associated with tautomeric nature of  the Quinazolinones  are often quite
complex and generally unpredictable. The recorded chemical investigation on the subject is
voluminous. The amide linkages in quinazolinones should not be looked on as predominantly
the keto or the enol form but as true keto-enol tautomers, showing reaction characteristic of
both the forms.
         Quinazolinones are always high melting crystalline solids, insoluble in water and in
most organic solvents but soluble in aqueous alkali. They are generally insoluble in dilute
acids  but  are  sometimes  soluble  in  concentrated  acids.  Simple  4(3H)-Quinazolinones,
although insoluble in dilute acids, are soluble in 6N hydrochloric acid. 4(3H)-Quinazolinones
form stable monohydrochlorides, chloroplatinate, chloroaurates and picrates and their metal
salts of silver, mercury, zinc, copper, sodium and potassium.
Stability of the ring system:
          The ring system in Quinazolinone is exceedingly stable in oxidation, reduction,
hydrolysis reactions and other treatment designed to break the ring. There is no report of
degradation of Quinazolinone by simple chemical oxidation.
Aromatization:
   When  a  simple  and  2-substituted-  4(3H)-Quinazolinone  is  heated  with  an  equivalent
amount  of  phosphorous  pentachloride  in  phosphorous  oxychloride,  the  corresponding  4-
chloroquinazoline is obtained. If a methyl group is present at 3-position, prohibiting the usual
tautomerism, the methyl group is lost during the chlorination.
Alkylation:
The  position  of  alkylation  of  Quinazolinones  is  similar  to  all  the  aromatic  nitrogen
heterocyclic  systems  in  which  a  hydroxyl  group  is  found  ortho  or  para  to  the  nitrogen
position.  Such  compounds  exist  in  tautomeric  mixture,  the  two  structures  being  inter-
convertible by the shift of one proton and one pair of electrons. In alkaline solution the ions
of such compounds exist as resonance hybrids of the two major forms differing only by the
position of two pairs of electrons, as shown. Thus in alkylation of such hydroxyl derivatives
of pyridine, pyrimidine and similar heterocycles, the entering group may become attached to
either the nitrogen atom, thus giving for instance, an N-alkyl-pyridine or to the oxygen atom,
giving an alkoxy pyridine.
Nitration:
4(3H)-Quinazolinone on boiling with nitric  acid  undergoes  substitution to  give 6-
nitro-4 (3H)-Quinazolinone. On further nitration it has been observed that the second nitro
group  enters  the  8-position  to  give  6,8-dinitro  derivatives.  2-Substituted-4(3H)-
Quinazolinones were also found to behave similarly, under such conditions.
Reduction:
2,3-Dihydro-3-methyl-  4(1H)-Quinazolinone  could  be  obtained  on reduction  of  3-
methyl-4(3H)-Quinazolinone with Lithium Aluminium Hydride (LiAIH4) in benzene.
Amino acids:
Amino  acids  are  organic  compounds,  containing  an  amino  group  and  a  carboxyl
group. Amino acids are the end product of protein digestion and the basic building blocks
from  which  proteins  digestions  and  the  basic  building  blocks  from  which  proteins  are
synthesized in the cell.
All proteins are made up of amino acids. Amino acids contains a carbon atom, a free
among group (containing  nitrogen-NH2) and a carboxyl group (COOH). Amino acids are
Amphoteric in reaction and forms salts with both acids and bases. Amino acids are colourless,
crystalline substance, soluble in water, easily diffusible and (except glycine) optically active.
When the amino and carboxyl groups of amino acids combine acid residue A peptide thus
consists of two or more amino acids linked by peptide bonds.
Amino acids  are  usually classified  by the  properties  of  their  side chain  into  four
groups.  The  side  chain  can  make  an  amino  acids  a  weak  acid  or  a  weak  base,  and  a
hydrophile  if  the  side  chain  is  polar  or  a  hydrophobe  if  it  is  nonpolar  .  The  chemical
structures of the 22 standard amino acids , along with their chemical properties, are described
more fully in the article on these proteinogenic amino acids. 
Zwitterions:
The amine and carboxylic acid functional groups found in amino acids allow them to
have  amphiprotic  properties.  Carboxylic  acid  groups  (-COOH)  can  be  deprotonated  to
become negative carboxylates (-CO2-), and α- amino groups (NH2-) can be protonated to
become positive α-ammonium groups (+NH3-). So has net zero charge. This molecular state
is known as a zwitterion, from the german zwitter meaning hermaphrodite or hybrid. Below
pH 2.2,  the  predominant  form will  have   neutral  carboxylic  acid  group  and  positive  α-
ammonium ion (net charge+1), and above pH 9.4, a negative carboxylate and neutral α-amino
group (net charge-1).
Zwitterions have minimum solubility at their isoelectric point and some amino acids
(in particular,  with non polar side chains) can be isolated by precipitation from water by
adjusting the pH to the required isoelectric point.
Amino acids have both a primary amine group and a primary carboxyl group, these
chemicals can undergo most of the reactions associated with these functional groups. These
include nucleophilic addition, amide bond formation and decarboxylation for the carboxylic
acid group.
Amino acids can be benzolyated in aqueous solutions of sodium hydroxide to avoid
racemisation and to improve the yield of benzoyl derivative18.
Chapter 2
Literature
Review
LITERATURE REVIEW
 BIOLOGICAL   ACTIVITIES OF QUINAZOLINES
Quinazolinone ring is an aromatic benzopyrimidine system many of it’s derivative
posses  interesting  biological  activities.   These  involve  analgesic,  anti-inflammatory,  anti-
hypertensive,  sedative  and  hypnotic  antihistaminic,  antitumour,  anti-microbial,  anti-
convulsant, antitubercular and many other activities. 
Most of the biological active Quinazolinones are having substitution at C-2 and N-3 position  
A brief review of pharmacologial activities exhibited by Quinazolinones is present here in.
ANTI-CONVULSANT ACTIVITY:
1. Hanan Georgey and Safinaz Abbas19;   A number of 3-substituted-2-(substituted-
phenoxymethyl)  Quinazoline-4(3H)-one  derivatives  synthesised  .A  preliminary
evalution of the anticonvulsant properties of the prepared compounds has indicated
that some of them moderate activity compared to a Diazepam standard.
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2. Sushil K. Kashaw and Varsha Kashawa20; A new 1-(4-substituted-phenyl)-3-(4-
oxo-2-phenyl-4H-Quinazoline-3-yl)-urea were synthesised and screened for 
anticonvulsant activity.
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ANTI – HYPERTENSIVE ACTIVITY
3. Rajiv  Dahiya  et.  al.21,  has  synthesized  and  carried  out  the  biological  activity  of
peptide  derivatives  of  iodoquinazolinones/nitroimidazoles.  Two  substituted
quinazolinyl/imidazolyl-salicylic  acids  5,  6  were  synthesized  by the  reaction  of  6
-iodo-2-methylbenzoxazin-4-one/5-nitroimidazole  with  5-aminosalicylic  acid  (5
-ASA).  Coupling  of  compounds  5  and  6  with  different  amino  acid  ester
hydrochlorides,  dipeptide  and  tripeptide  methyl  esters  yielded  novel
quinazolino/imidazolopeptide  derivatives.  6f  and  its  hydrolyzed  derivative  6fa
showed  good  anthelmintic  activity  against  Megascoplex  konkanensis,  Pontoscotex
corethruses and Eudrilus eugeniea at dose of 2 mg ml–1.
                              
Quinazolinone derivative, ketanserin exhibits anti – hypertensive activity and is an 
antagonist of 21 – ADRENERSIC AND SEROTENIN  S2 RECEPTORS
                                              
ANTI – CANCER ACTIVITY
4. Jones and co-workers22 has reported that {N- [4-(2-amino – 3,4 – dihydro-4- oxo-6-
quinazolyl) Methyl] –N-Prop-2-Ynyl amino] benzoyl}- L –Glutamic acid has been
found  to  be  a  selective  thymidylate  synthetase  (TS)(4)   inhibitors.   It  has  shown
encouraging anti-tumor activity against breast and ovarian cancers in recent clinical
trials. The compound has shown 50 – fold improvement over in therapeutic index.
                                   
 
ANALGESIC AND ANTI – INFLAMMATORY ACTIVITY
5. Rita Nigam et al23., has prepared quinazolin -4 (3H) ones for anti- inflammatory 
activity.
                            
6. Hithari,  etal24., has  reported  synthesis  of  6  substituted  -2-alkyl-3-(4-
aminobenzenesulphonamido)  quinazolin-4-(3H)-one  and  its  anti-  inflammatory
activity.
                            
ANTIMICROBIAL ACTIVITY
7. PRADEEP MISHRA, SANMATHI K. JAIN AND SANDEEP JAIN25, synthesized 
some new Quinazolin 4(3H) ones (II) as possible antimicrobial agents.
                                  
N
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8. CH.RAJVEER et. al.26, has carried out for the synthesis of 2-(6-bromo-2-phenyl-4
oxoquinazolin-3(4H)-yl)-N-substituted  acetamides  and  1-Amino-5-(6-  bromo-3,  4-
dihydro-2-phenyl-4-oxoquinazolin-3yl) methyl-1, 3, 4-triazin-2-thiol to carry out their
pharmacological activities. The synthesized compounds were screened for their anti-
bacterial  activity,  anti-inflammatory  activity  and  analgesic  activity  by  standard
methods.  The compound shows Pharmacological  activities in comparison with the
standard.
                            
9. B.Shivarama Holla et al27., describes the synthesis and characterization of some 
fluorine containing arylfuryl vinyl quinazolinones as possible antibacterial agents.
                                         
10. Remy C.Lemoine et al (2004)28,.reported the discovery of a series of quinazoline
based fungal efflux pump inhibitors by high-throughput screening for potentiation of
flucanazole.  Attempts  to  improve  the  aqueous  solubility  of  screening  hits  led  to
improved physical properties and activity against clinically-relevant candida spp.
                                                 
3-(3-chlorophenyl)-1-(1-(3,4-dihydro-4-oxo-3-(piperazin-1-yl)quinazolin-2-yl)ethyl)-1-(2,4-
dimethoxyphenyl)urea
ANTIVIRAL ACTIVITY
11. Nilgun Karali et al29 , reported new esters and hydrazides were synthesized from 6-
methyl/fluro-3-phenyl-4(1H, 3H)-quinazolinone-2-thiones. Compound was confirmed
moderately active against HIV-1.
                                      
                                                R1 ,R2=        H,Br
ANTI-TUBERCULAR ACTIVITY;
12. A series of 21 new 2-alkylthio-6-iodo-3-substituted-quinazolin-4-one derivatives was 
prepared andscreened for their in vitro antitubercular activity against Mycobacterium 
tuberculosis strain H Rv, using the 37  radiometric BACTEC 460-TB 
methodology.Active compounds were also screened by serial dilution to assess 
toxicity to a VERO cell line.
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13. Shukla and Rastigum30, has synthesized a series of 2-substitued quinazoline4(3H)-
ones  and  tested  for  their  anti  helmintic  activity  against  Brugia  Pahangi  and
Hymenoepis nanc in birds and rates Compound 2 – [3-substituted amino methyl-l-4’-
hydroxy phenyl] quinazolin- 4(3H) – one (43) is found to be most active member of
the series, showing 65% clearance of H.  an infestation at a dose 250mg/Kg for 3
days.
                                                 
14. MS Amine et al31., has reported the uses of quinazolin-2-[-Propionoyl] isothio 
cyanate]-4 ne as a building block in synthesis of some heterocyclic compounds of 
expected biological activities.
                                                   
15. PSR Reddy et al.32,  has reported A facile synthesis of 1 – ary 1-4 –{isopropylidene 
amine /methyl -4-(3h) – oxoquinazolin -2-4}] azetidin-2 ones.
                                       
16. Shukla,  et  al33., has  reported  antimalarial  activity  of  2-  aryloxymethyl-3[p’-
nitrophenylthio) phenyl] quinazoline-4(3H) one which is having ED50 <10mg. Kg. and
ED 90>10mg/Kg. 
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        Aim and Objectives
AIM OF THE PRESENT WORK
 Cancer is a class of diseases characterized by out-of-control cell growth which harms the
body by forming lumps or masses of tissue called tumors. Tumors are invasive, aggressive
and mostly metastatic. Cancer is life threatening due to cells that uncontrollably grow and do
not die. Under stress,  our  bodies  produce more reactive oxygen species (e.g.,  superoxide
anion radicals, hydroxyl radicals and hydrogen peroxide) than enzymatic antioxidants (e.g.,
superoxide dismutase, glutathione peroxidase and catalase) and non-enzymatic antioxidants
(e.g.,  ascorbic acid,  tocopherol,  glutathione,  carotenoids,  and flavonoids).  This  imbalance
leads to cell  damage and health problems.  A lack of antioxidants,  which can quench the
reactive  free  radicals,  facilitates  the  development  of  degenerative  diseases,  including
cardiovascular  diseases,  cancers,  neurodegenerative  diseases,  Alzheimer’s  disease  and
inflammatory diseases.       
Microorganisms like bacteria and fungi cause many infections like meningitis, ottis media,
pneumonia,  cholera,  food  poisoning,  urinary tract  infections,  aspergillosis,  candidose etc.
Many of these diseases are fatal if  untreated,  and treatment has been complicated by the
resistance  of  the  microorganisms  to  the  widely  used  drugs.  To  combat  the  problem  of
resistance newer drugs are needed.
Numerous research has shown that the Quinazoline nucleus possesses potent activity against
human cancer  particularly by killing the specific  tumor cells.  The nucleus  has also been
reported to have anti oxidant and potent antimicrobial activities. These observations gave us a
great impetus to the search for potential  biological  active drugs carrying 2,3-disubstituted
Quinazoline-4(3H)-one in combination with amino acids and sulfonyl hydrazides, hoping to
add some synergistic biological significance to the target molecules to get potent anti oxidant,
anti tumor and antimicrobial agents.
Quinazolinone ring is an aromatic benzo pyrimidine system. The Quinazolinone nucleus have
attracted the attention of medical chemist due to a wide range of biological activity exhibited
by them.
 Quinazoline 4(3H) one constitute a unique group of compound due to the simultaneous 
presence of three characteristic feature 
1. Enormous synthetic possibilities are offered by the presence of acetanthranils, often 
serve as starting material for more complex compounds via cyclization, condensation 
etc.,
2. Stability of the nucleus and
3.  Wide range of biological activity.
 Structural modifications involving variations in the nature of groups in the 2 and 3 positions 
and substitution into fused benzene ring have lead to a large number of derivatives that are 
biologically active.
Interests in quinazolines as anticancer agents have further increased since the discovery of  
Raltitrexed and Thymitaq proved to be Thymidylate enzyme inhibitors in cancer treatment.
 In order to produce potent new leads for anticancer drugs, a new series of 2,3 di substituted
Quinazolin4(3H)one analogue have been designed by fusing with some biologically friendly
amino  acids  and  some sulfonyl  hydrazide   the  structural  features  which  are  believed  to
enhance tumor inhibition activity.
Amino  acids  conjugated  Quinazolinones  are  reported  to  have  a  greater  binding  affinity,
enhanced anti tumor and antimicrobial activity34
Amino acids will minimize the side effects of the metabolite of the parent compound upon
metabolism in the body and enhance the solubility of the synthesised candidates when it is
incorporated into pharmacologically active Quinazolinone moiety34.
. The objective of the following work can be summarized as follows :
 Synthesis of some Novel 2, 3-disubstituted-4(3H)-Quinazolinone derivatives.
 Characterization of the synthesized compound using the various analytical and 
spectral techniques.
 Screening for Anti Oxidant activity by DPPH & FRAB method.
 Screening for In vitro Anti tumor activity against human cervical cancer cell line 
(HeLa) by MTT assay method.
 Screening for the Antimicrobial activity against various microorganisms using Disc    
diffusion method.
                                
                                
Chapter 4
Experimental
Procedure
EXPERIMENTAL
Scheme -1:
Step-1:
Synthesis of 2-chloro benzyl 1, 3-benzoxazin-4-one:
A mixture of Para chloro phenyl acetic acid (0.06 mol) and phosphorous penta chloride (0.06
mol) was triturated to get  chloro phenyl  acetyl  chloride.  Anthranilic acid (0.06 mol) was
dissolved in 30ml of anhydrous pyridine by stirring slowly at room temperature, cooled to 00
c and a solution of chloro phenyl acetyl chloride in anhydrous pyridine 30ml was added to
this solution slowly with constant stirring.35 When the addition was complete the reaction
mixture was stirred for half an hour mechanically at room temperature and set aside for 1 hr.
The pasty mass obtained was diluted with water and treated with aqueous sodium bicarbonate
to remove the un reacted acid when effervescence ceased, The solid material was filtered off
and  washed  with  water  to  remove  the  inorganic  material  adhered  pyridine.  The  crude
benzoxazinone thus obtained was dried and re-crystallized from dilute ethanol. 
Step-2:
Synthesis of 4-[2-(4-chlorobenzyl)-4-oxoquinazolinone-3(4H)-yl) benzoic acid:
 10gm of 2-chlorobenzyl 1,3-benzoxazin-4-one was added to a mixture of 4- amino  benzoic
acid (6.31gm) and glacial acetic acid(30ml) and the mixture was refluxed under anhydrous
condition for 6hrs. After then added ice cold water into it  and the crude the product was
filtered and dried. The crude product was recrystallised from 1,4-dioxane..
Step-3:
Synthesis of 4-[2-(4-chlorobenzyl)-4-oxoquinazolinone-3(4H)-yl) benzoyl chloride:
A solution of 4-[2-(4-chlorobenzyl)-4-oxoquinazolinone-3(4H)-yl) benzoic acid (7.03gm) in
1,4-dioxane (20ml) was placed in a 250ml flask fitted with a condenser . Thionyl chloride
(2ml) was then added drop wise to the flask using dropping funnel. The mixture was refluxed
under  anhydrous  condition  for  4hrs.  The  excess  of  thionyl  chloride  was  removed  by
distillation. The reaction mixture was poured into the 100ml ice cold water and the crude
product was filtered and dried. The dried crude product was recrystallised from 1,4-dioxane.
Step-4:
Synthesis of 4-[2-(4-chlorobenzyl)-4-oxoquinazolinone-3(4H)-yl) benzoyl] derivatives
Asolutionof4-[2-(4-chlorobenzyl)-4-oxoquinazoline3(4H)yl)benzoylchloride(4.1gm.0.01mol)
in 1,4-dioxane was added to corresponding amino acid (0.01mol) and sulfonyl Hydrazide  in
0.1N sodium hydroxide (10ml) and the mixture was refluxed for 6hrs.36 The reaction mixture
was then poured into 1N Hydrochloric acid (50ml) and the crude products were filtered and
dried. The dried products were recrystallised from 1, 4-dioxane.
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CHARACTERIZATION
MELTING POINT: 37
Melting points of the synthesized compounds were determined in a one end fused
capillary tube method by using Thermonic Model –C-LMP- 1 CAMPVEEL melting point
apparatus, and were uncorrected..
 THIN LAYER CHROMATOGRAPY:
Thin layer chromatographic analysis was carried out for all synthesized compounds
by using silica gel G (0.5mm thickness) coated over glass plate (12 x 20 cm) as stationary
phase,  Acetonitrile:  EthylAcetate:  Methanol  (1:1:1)  as  mobile  phase  and  the  spot   was
visualized by iodine vapor. 
ULTRA VIOLET SPECTRAL ANALYSIS:
The maximum absorbance or λ max of synthesized compounds was determined in the
concentration of 0.01% w/v in DMF by using shimadzu 2000 ultraviolet spectrophotometer. 
INFRARED SPECTRAL ANALYSIS: 38
The  structures  of  the  synthesized  compounds  were  elucidated  by  JASCO  FT-IR
spectrophotometer in KBr disc. The IR value is measured in cm-1.
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY:
The structures of the synthesized compounds were to be elucidated by Bruker 300
MHz  FT-  NMR  using  TMS (Tetramethylsilane)  as  internal  standard.  The  PMR  (Proton
Magnetic Resonance) spectroscopic values are measured in δ ppm in DMSO.
MASS SPECTROSCOPY:
The structures of the synthesized compounds were to be elucidated by MS (EI) JEOL GC
MATE 700EV Mass spectroscopy. The mass spectroscopic values are measured in m/e ratio.
PHYSICO-CHEMICAL PARAMETERS OF SYNTHESISED DERIVATIVES
S.N
o
Compound
Code.
Molecular
formula
Molecular
weight
Melting
point
Rf
value solubility
Percentag
e
yield
1. C-GY C24H18ClN3O4 447.87 195 0.34 Ethanol/DMSO 72%
2. C-GU C27H22ClN3O6 519.93 205 0.58 Ethanol/DMSO 78%
3. C-PA C31H24ClN3O4 537.99 246 0.38 Ethanol/DMSO 69%
4. C-TY C31H24ClN3O5 553.99 256 0.72 Ethanol/DMSO 82%
5. C-CY C25H20ClN3O4S 493.96 225 0.68 Ethanol/DMSO 74%
6. C-HS C28H22ClN5O4 527.96 198 0.44 Ethanol/DMSO 86%
7. C-TP C33H25ClN4O4 577.03 270 0.32 Ethanol/DMSO 93%
8. C-PT C29H23ClN4O4S 559.04 246 0.62 Ethanol/DMSO 86%
9. C-2 C31H27ClN4O4S 587.06 298 0.74 Ethanol/DMSO 92%
10. C-HH C22H17ClN4O2 404.85 185 0.46 Ethanol/DMSO 76%
SPECTRAL STUDIES
SPECTRAL DATA OF THE SYNTHESIZED COMPOUNDS43
Co
de
Structure IR(cm-1) NMR(δ
ppm)
MASS(
m/z,
amu)
C-
GY
2923.03(COOH
Stretching)
1675.05(C=O
Stretching)
1592.91(C=N
Stretching)
1299.79(C-N
Stretching)
789.70(Chlorine
group  Stretching)
7.4 –
7.9 (d,
4H,
ArH)
8.0 (t,
1H,NH)
3.7 (S,
2H,CH2
)
10.7(S,
1H,
COOH)
M/Z(44
6.98)
Base
peak(14
2.97)
C-
GU
3127.15(COOH
Stretching)
1675.05(C=O
Stretching)
1592.91(C=N
Stretching)
1200.20(C-N
Stretching)
780.07(Chlorine
group Stretching)
C-
PA 3142.15(COOH
Stretching)
1616.20(C=C
Stretching in
aromatic)
1592.91(C=N
Stretching)
780.07(Chlorine
group Stretching)
697.15(MonoSubst
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C-
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Stretching)
3142.15(COOH
Stretching)
1596.91(C=N
Stretching)
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Stretching)
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4H, ArH)
2.1(S,
1H, CH2)
2.2-
2.6(S,
3H,CH3)
C-
HH
3338.12(NH2
Stretching)
1503.24(C=N
Stretching)
1164.79(C-N
Stretching)
790.03 (C-Cl
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Chapter 5
        
         Biological Screening
BIOLOGICAL SCREENING
INVITRO ANTI-OXIDANT SCREENING OF SYNTHESIZED COMPOUNDS
 In-vitro Anti-oxidant screening of synthesized compounds were done by using three 
methods 
 DPPH method
 FRAP method and 
Determination of DPPH (1-1-diphenyl 2-picryl hydrazyl) radical-scavenging activity:
Procedure:39
The free radical-scavenging activity of the synthesized compounds were measured in terms of
hydrogen  donating  or  radical-scavenging  ability  using  the  stable  radical  DPPH.  0.1  mM
solution of DPPH in ethanol was prepared and 1.0 ml of this solution was added to 3.0 ml of
extract solution in methanol at different concentrations (0.1–5 mg/ml). Thirty minutes later,
the absorbance was measured at 517 nm. Ascorbic acid was used as the reference compound.
Lower absorbance of the reaction mixture indicated higher free radical-scavenging activity.
Radical scavenging activity was expressed as the inhibition percentage of free radical by the
sample and was calculated using the following formula:
where A0 was the absorbance of the control (blank, without compounds) and At was the
Absorbance in the presence of the compounds. All the tests were performed in triplicate and
the graph was plotted with the mean values.
Ferric reducing antioxidant power (FRAP) assay:39
FRAP assay is based on the ability of antioxidants to reduce Fe3+ to Fe2+ in the presence of
2,4,6-tri(2-pyridyl)- s-triazine (TPTZ), forming an intense blue Fe2+-TPTZ complex with an
absorption  maximum at  593  nm.  This  reaction  is  pH-dependent  (optimum pH 3.6).  The
absorbance decrease is proportional to the antioxidant content (Benzie and Strain, 1996). 0.2
ml of the compound is added to 3.8 ml of FRAP reagent (10 parts of 300 mM sodium acetate
buffer at pH 3.6, 1 part of 10.0 mM TPTZ solution and 1 part of 20.0 mM FeCl3. 6H2O
solution)  and  the  reaction  mixture  is  incubated  at  37°C for  30  min  and  the  increase  in
absorbance at 593 nm is measured. FeSO4 is used for calibration. The antioxidant capacity
based on the ability to reduce ferric ions of sample is calculated from the linear calibration
curve and expressed as mmol FeSO4 equivalents per gram of sample. BHT, BHA, ascorbic
acid, quercetin, catechin or trolox can be used as a positive control.
% inhibition= (A0 - At)/ A0
IN VITRO ANTICANCER SCREENING OF SYNTHESIZED COMPOUNDS
BY MTT ASSAY METHOD
MTT ASSAY
PRINCIPLE
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole), is
reduced  to  purple formazan by mitochondrial  succinate dehydrogenase in living cells.The
MTT enters the cells and passes into the mitochondria where it is reduced to an insoluble,
coloured (dark purple) formazan product. The insoluble purple formazan product is converted
to a colored solution using a solubilization agent (usually either DMSO, an acidified ethanol
solution, or a solution of the detergent sodium dodecyl sulfate in diluted hydrochloric acid).
The  absorbance  of  this  colored  solution  is  then  quantified  by  measuring  at  a  certain
wavelength (usually between 500 and 600 nm) by a spectrophotometer. Since reduction of
MTT can only occur in metabolically active cells, this assay gives a direct  measure of the
viability of cells.
The human cervical cancer cell line (HeLa) was obtained from National Centre for
cell Science (NCCS), Pune. The cells were grown in Eagles Minimum Essential Medium
containing 10% fetal bovine serum (FBS).
For screening experiment,40 the cells  were seeded into 96-well  platesin 100µl of medium
containg 5% FBS, at plating density of 10,000 cells/well and incubated at 370C, 5% CO2,
95% air and 100%  relative humidity for 24 h prior to addition of samples. The samples were
solubilised in Di methylsulfoxide and diluted in serum free medium. After 24h , 100µl of the
medium containg the samples at various concentration (eg; 6.25, 12.5, 25, 50mM etc…..) was
added  and  incubated  at  370C,  5%  CO2,  95%  air  and  100%  relative  humidity  for  48h.
Triplicate  was  maintained  and  the  medium  containing  without  extracts  were  served  as
control.
After 48h,15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) was added to each well
and incubated at 370C for 4h. the medium with MTT was then flicked off and the formed
formazen crystals were solubilized in 100 µl of DMSO and then measured the absorbance at
570nm using micro plate reader. The % cell inhibition was determined using the following
formula.
 % cell inhibition = 100- Abs (sample)/Abs (control) x 100.
Non-linear regression graph was plotted between % cell inhibition and Log10 concentration 
and IC50 was determined using Graph Pad Prism Software.  
ANTI-BACTERIAL SCREENING OF THE SYNTHESIZED COMPOUNDS
BY DISC DIFFUSION METHOD
PROCEDURE:
Preparation of Muller Hinton Agar Medium:
            Composition of Muller Hinton Agar Medium
SL.NO INGREDIENTS QUANTITY
1 Beef extract 10g
2 Casein acid hydrolysate 17.5g
3 Starch 1.5g
4 Agar 20 g
5  Distilled water 1000ml
Specified amount of Muller Hinton agar was taken along with 1000ml of distilled water in a
conical flask and heated in a steam bath to dissolve. The pH was maintained at 7.6 ± 0.2 and
sterilized in an autoclave at 15 lb pressure, 120°C for 15 minutes. The sterile medium was
poured into the sterile Petri dish and allowed to solidify. 
Preparation of plates:
Muller  Hinton agar  medium was prepared  and  transferred  into sterile  Petri  plates
aseptically (thickness of 5-6mm). The plates were allowed to dry at room temp. The plates
were inverted to prevent condensate falling on the agar surface. The layers of the medium are
uniform  in  thickness,  is  done  by  placing  the  plates  on  a  leveled  surface.  Standardized
bacterial inoculums of  Vibrio cholera, Escherchia coli, Bacillus subtilis,  Bacillus linctus,
Micrococcus luteus, Staphylococcus aureus, Klebsiella pneumonia, Coryne bacterium  were
applied to the plates and spreaded uniformly over the surface of medium by using a sterile
Non-absorbent cotton swab and finally the swab was passed around the edge of the medium.
The inoculated plates were closed with the lid and allowed to dry at room temperature. The
sample impregnated discs (10µg /disc) in dimethyl  sulphoxide and standard ciprofloxacin
5µg disc were placed on the inoculated agar medium. All petriplates were incubated at 37˚C
for 24 hrs. After the incubation diameter of zone of inhibition produced by the sample were
measured. The antibacterial activity was evaluated by measuring zone of inhibition in mm.
Determination of Minimum Inhibitory Concentration of Synthesized Compounds 
(MIC) by Serial dilution method:
 The serial dilution of known concentration of compound solution was made from the 
stock (100 mg/ml) by using Muller Hinton broth using the method described below.
 The tubes were labeled 1 to 8 and 1 ml of Muller Hinton broth were added to the first 
5 tubes and 8th tube, then added 0.5 ml Muller Hinton broth to 6th and 7th tubes. 
 One ml of different synthesized compounds was added to the 1st tube, mixed and 
transfer 1ml serially up to tube 5.From the 5th tube transfer 1ml to 6th tube. Mixed 
and transfer 0.5 ml to the 7th tube. Each tube, 1 to 7 contains 1ml diluted extract.
 The 8th tube was the control. 
 With a standardized micro pipette, add a drop of the diluted broth culture 
approximately 0.01ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 37 0 c for 24hrs.
 The highest dilution of particular compounds showing no turbidity was observed and 
recorded. This was taken as the end point, and this dilution was considered to contain 
the concentration of drug equivalent to MIC. 
ANTI-FUNGAL SCREENING OF THE SYNTHESIZED COMPOUNDS
BY DISC DIFFUSION METHOD
PROCEDURE
Preparation of Sabourands dextrose broth: 41’42
     Composition of Sabourands dextrose broth
   
Specified amount of dextrose and peptone was taken along with 1000ml of distilled water in 
a conical flask and heated in a steam bath to dissolve. The pH was maintained at 7.6 ± 0.2 
and sterilized in an autoclave at 15 lb pressure, 120°C for 15 minutes. The sterile medium 
was poured into the sterile Petri dish and allowed to solidify. 
Preparation of plates:
Sabourands dextrose broth medium was prepared and transferred into sterile Petri plates 
aseptically (thickness of 5-6mm). The plates were allowed to dry at room temp. The plates 
were inverted to prevent condensate falling on the agar surface. The layers of the medium are 
uniform in thickness, is done by placing the plates on a leveled surface. Standardized fungal 
inoculums of Aspergillus niger, Aspergillus fumigatus, Aspergillus parasiticus, Candida 
albicans, were applied to the plates and spreaded uniformly over the surface of medium by 
using a sterile Non-absorbent cotton swab and finally the swab was passed around the edge of
the medium. The inoculated plates were closed with the lid and allowed to dry at room 
temperature. The sample impregnated discs (10µg /disc) in dimethyl sulphoxide and standard 
Clotrimazole 10µg/disc were placed on the inoculated agar medium. All petriplates were 
incubated at 27˚C -28˚C for 48 hrs. After the incubation diameter of zone of inhibition 
produced by the sample were measured.
Determination of Minimum Inhibitory Concentration for Synthesized Compounds 
(MIC) by Serial dilution method:
 The serial dilutions of known concentration of compound solution are made from the 
stock (100 mg/ml) by using Sabourands dextrose broth using the method described 
below.
SL.NO INGREDIENTS QUANTITY
1 Dextrose 40g
2 peptone 10g
3 water 1000ml
 The tubes were labeled 1 to 8 and 1 ml of Sabourands dextrose broth were added to 
the first 5 tubes and 8th tube, then added 0.5ml of  Sabourands dextrose broth  to  6th 
and 7th tubes. 
 One ml of different synthesized compounds was added to the 1st tube, mixed and 
transfer 1ml serially up to tube 5.From the 5th tube transfer 1ml to 6th tube. Mixed 
and transfer 0.5 ml to the 7th tube. Each tube, 1 to 7 contains 1ml diluted extract.
 The 8th tube was the control. 
 With a standardized micro pipette, add a drop of the diluted broth culture 
approximately 0.01ml of the test organism to all tubes, including the control, gently 
mixed and incubated at 26-28 0 c for 48hrs.
 The highest dilution of particular compounds showing no turbidity was observed and 
recorded. This was taken as the end point, and this dilution was considered to contain 
the concentration of drug equivalent to MIC.
Chapter 6
      
   
Results and
Discussion
ANTI OXIDANT SCREENING
Anti Oxidant activity of synthesized compounds
INVITRO ANTIOXIDANT 
DPPH RADICAL SCAVENING ACTIVITY:
DPPH Radical scavenging (antioxidant) activity was determined by the
method modified by Hatano et al.,(1989).
Percentage of Inhibition 
Concen
tration
C-TY C-GY C-GU C-CY C-HS C-PT C-T C-HH C-TP C-PA Ascorbic 
Acid
25µ 35.59 44.72 45.17 29.36 16.96 45.92 72.24 47.52 43.76 45.40 56.7
50µ 44.49 45.71 53.00 43.40 37.09 49.41 53.52 46.59 46.56 41.97 68.9
75µ 49.69 47.46 97.12 78.71 78.70 44.60 65.11 67.14 48.87 49.51 89.0
100µ 50.51 48.37 98.36 45.56 45.56 46.76 93.34 63.58 49.07 46.58 96.0
EC50 35 27 28 42 73 28 17 26 26 27 22
ANTIOXIDANT ACTIVITY OF COMPOUNDS C-TY,C-GY,C-GU,C-TP AND
ASCORBIC ACID
ANTI OXIDANT SCREENING
Anti Oxidant activity of synthesized compounds
INVITRO ANTIOXIDANT 
Ferric reducing antioxidant power (FRAP) assay:
Absorbance
Con
cn
C-TY C-GY C-GU C-CY C-T C-HS C-PT C-PA C-TP C-HH Ascorbic 
Acid
25µ 0.0274 0.1021 0.1568 0.3673 0.2653 0.8768 0.2665 0.4903 0.0038 0.2758 0.9504
50µ 0.2055 0.3565 0.2743 0.4057 0.5086 0.7270 0.4601 0.4124 0.1366 0.6385 1.0020
75µ 0.4974 0.5612 0.4733 0.5469 0.5358 0.8258 0.3990 0.2229 0.4328 0.3083 1.1843
100µ 0.6940 0.9269 0.6853 0.1526 1.1480 0.4065 0.1148 0.3968 0.5398 0.1767 1.2743
R2 0.95 0.95 0.96 0.75 0.62 0.85 0.79 0.52 0.95    0.65 0.98
ANTIOXIDANT ACTIVITY OF COMPOUNDS C-TY,C-GY,C-GU,C-
TP AND ASCORBIC ACID
In vitro anticancer screening
HeLa cell line inhibition by the synthesised compound(C-PT)
Conc(µm
)
% cell 
Inhibition
conc 0.1(µm) 1(µm) 10(µm) 100(µm) contro
l
0.1 1.136364 ABS 0.396 0.394 0.381 0.357 0.415
1 1.948052 0.41 0.402 0.385 0.366 0.391
10 6.980514 0.412 0.412 0.38 0.377 0.426
100 10.71429 Avg 0.406 0.402 0.382 0.366 0.410
IC50  >100
HeLa cell line inhibition by the synthesised compound(C-GU)
Conc(µm
)
% cell 
Inhibition
conc 0.1(µm) 1(µm) 10(µm) 100(µm) control
0.1 2.001334 ABS 0.469 0.355 0.158 0.023 0.476
1 29.21948 0.492 0.357 0.158 0.041 0.496
10 68.57905 0.508 0.349 0.155 0.035 0.527
100 93.39872 Avg 0.48927 0.5328 0.157 0.033 0.4996
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Photograph of HeLa cell line inhibition by the synthesised compound(C-GU)
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HeLa cell line inhibition by the synthesised compound(C-T)
Conc(µm
)
% cell 
Inhibition
conc 0.1(µm) 1(µm) 10(µm) 100(µm) control
0.1 -0.40027 ABS 0.503 0.464 0.315 0.117 0.476
1 10.07338 0.498 0.445 0.323 0.103 0.496
10 35.3569 0.504 0.439 0.331 0.099 0.527
100 78.71915 Avg 0.501 0.449 0.323 0.106 0.499
HeLa cell line inhibition by the synthesised compound(C-GY)
Conc(µm
)
% cell 
Inhibition
conc 0.1(µm) 1(µm) 10(µm) 100(µm) control
0.1 1.13632 ABS 0.4 0.372 0.359 0.353 0.415
1 7.95454 0.42 0.376 0.362 0.351 0.391
10 11.85065 0.398 0.386 0.365 0.35 0.426
100 14.44805 Avg 0.406 0.378 0.362 0.351 0.410
Photograph of HeLa cell line inhibition by the synthesised compound(C-T)
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RESULT
Sr.no Compound    Conc (µm) %cell 
Inhibition
IC50(µm)
1 C-GY      0.1 1.13632
     _
       1 7.95454
      10 11.85065
     100 14.44805
2 C-GU       0.1 2.001334
   3.5(µm)
        1 29.21948
       10 68.57905
      100 100.9339
3 C-PT       0.1 1.13634
      _
                 
        1 1.94805
       10 6.980519
      100 10.71429
 4 C-T        0.1 -0.40027    20.27(µm)
         1 10.07338
        10 35.3569
       100 78.71915
Anti bacterial screening Disc diffusion method :
S.
No 
Micro 
Organis
m Zone of Inhibition 
Compound (10µg/disc) 
C-
GY
C-
G
U
C-
PA
C-
TY
C-
C
Y
C-
HS
C-
TP
C-
PT
C-
T
C-
HH
STD
Ciprofloxacin 
(10µg/disc) 
1. M.luteu
s 
12 - - 3 3 10 - - 12 15 16
2. S.aureu
s 
13 6 5 4 2 6 14 7 14 16 17
3. B.subtil
is 
10 4 5 - 3 7 5 4 6 11 17
4. C.dipht
heriae 
9 3 3 - 3 11 - - 4 12 13
5. E.coli 4 - 11 3 4 10 5 3 6 14 17
6. P.aureg
inosa 
11 - 3 4 - 3 5 4 7 15 16
7. R.rubru
m 
- 3 - 11 - 11 4 3 3 13 15
8. V.choler
ae 
- 13 3 3 13 - - 3 16 17
SERIAL DILUTION METHOD
MIC values of the synthesized compounds
S.No Micro 
organism 
MIC VALUES (µg/ml) 
1. M.luteus 1.25 5 5 10 10 1.25 5 5 1.25 1.25
2
.
S.aureus 1.25 2.5 2.5 2.5 10 2.5 1.2
5
1.2
5
1.25 1.25
3
.
B.subtilis 1.25 2.5 2.5 5 10 1.25 2.5 2.5 1.25 1.25
4
.
C.diphtheri
ae 
1.25 10 10 5 10 1.25 5 5 5 1.25 
5
.
E.coli 2.5 5 1.25 10 2.5 1.25 2.5 2.5 2.5 1.25
6. P.aureginos
a 
1.25 5 10 2.5 5 10 2.5 2.5 1.25 1.2 5
7. R.rubrum 5 10 5 1.2
5
5 1.25 10 10 2.5 1.25 
8. V.cholerae 2.5 5 1.25 10 10 1.25 5 5 2.5 1.25
                                    
Anti bacterial screening:
Micrococcus luteus
Staphylococcus aureus
Basillus subtitiles
Corynebacterium diphtheria
 
Eschercia coli
 
Pseudomonas aureginosa
 
Vibreo cholera
Antifungal screening
 Disc diffusion method
S.No Micro organism Zone of Inhibition 
Compound (10µg/disc) 
C-GY C-GU C-PA C-TY C-
CY
C-
HS
C-TP C-PT C-T C-HH STD
Clotrimazole
(10µg/disc) 
1. Candida 
albicans 
6 5 - 3 3 - 4 3 3 - 6
2. Streptomyces 
Gresus 
4 5 3 4 - 5 4 - - - 7
3. Aspergillus 
Niger 
5 - 4 3 8 5 6 4 - - 5
4. Aspergillus 
Fumigalis 
4 7 3 5 3 - 3 6 - - 5
5. Monasus ruber - 4 - 5 3 6 4 4 - - 6
SERIAL DILUTION METHOD
MIC Values of the synthesized compounds
S.N
o 
Micro 
organism 
MIC  Values (µg/ml)                    
C-
GY
C-GU C-
PA
C-TY C-CY C-HS C-TP C-PT C-T C-HH
1. Candida 
albicans 
1.25 1.25 5 10 10 5 2.5 10 10 5
2. Streptomyce
s 
Gresus 
2.5 1.25 10 2.5 5 2.5 2.5 5 5 5
3. Aspergillus 
Niger 
2.5 5 2.5 10 1.25 2.5 1.25 2.5 5 5 
4. Aspergillus 
Fumigalis 
2.5 1.25 10 2.5 10 5 10 1.25 5 5 
5. Monasus 
ruber 
5 2.5 5 2.5 10 1.2 2.5 2.5 5 5 
Antifungal screening:
Candida albicans
Streptomyces gresus
Aspergilus niger
Aspergilus fumigalis
Monococus ruberum
                                                                                                                
                                                                                                   
                                                                                                                         
Result and Discussion
 Interaction of p- chloro phenyl acetic acid with phosphorous penta chloride afforded
phenyl  acetyl  chloride  which  on  reaction  with  anthranilic  acid  and  pyridine  yields
corresponding 2-chloro benzyl 1,3-benzoxazine-4-one derivative.
 
Reaction of compound 
 
with para amino benzoic acid in glacial acetic acid afforded 4-
[2-(4-chlorobenzyl)-4-oxoquinazolinone-3(4H)-yl]benzoic  acid.  This  was  subsequently
reacted  with  thionyl  chloride,  to  give  4-[2-(4-chlorobenzyl)-4-oxoquinazolinone-3(4H)-yl]
benzoyl derivativies. After the reaction compound added amino acids and sulfonylhydrazide
compounds.
The  physical  parameters  like  melting  point,  molecular  weight,  of  the  synthesized
compounds were determined. 
The melting points of the synthesized compounds determined and were uncorrected,
and melting range was found to be between, 185-298ºC
The structure of the synthesized compound was confirmed by IR, MASS and NMR
spectral analysis.
ANTI – OXIDANT ACTIVITY
The synthesized compounds were tested for anti-oxidant activity by DPPH and FRAP
assay method at the concentration of 25µg/ml, 50µg/ml, 75µg/ml and 100µg/ml in DMSO.
Ascorbic acid was used as standard. Compounds C-TY, C-GU, C-GY and C-TP were shown
good anti oxidant activity with EC- 50 value of 35, 27, 28 and 26 µg.
ANTI-CANCER ACTIVITY
The In vitro anticancer studies were performed on 4 selected compounds using MTT
assay against HeLa cell line (NCCS). The results indicated that among the four compounds
tested, the compound C-GU and C-T only  inhibited the proliferation of cancer cells.
Antibacterial activity:
The anti-bacterial studies could be seen that all the synthesized derivatives showed 
moderate to good activity against the used gram(+ve) and gram(-ve) bacteria.
The MIC of the synthesized compounds against gram (+ve) and gram (-ve) bacteria 
determined by serial dilution method, was found to be in the range of 1.25 – 5 µg/ml.
Antifungal activity :
The anti-fungal studies showed that synthesized Quinazolinone derivatives exhibits 
moderate to good anti-fungal activity against organisms, with zone of inhibition in the range 
of 2-7mm.
In that the compound C-HH,C-T,C-GY,C-HS ,C-GU showed good activity with the 
zone of inhibition in the range of 8mm.
The MIC of the synthesized compounds against microorganisms against organisms 
determined by serial dilution method, was found to be in the range of 1.25 - 5µg/ml.
Chapter 7
Conclusion
CONCLUSION
Some novel 2,3-disubstituted-3H-Quinazolin-4-one derivatives with the aim and to
get more potent drug for the treatment of Anti tumor and microbial infectious diseases.
The structure of the compounds was confirmed by spectral analysis. The synthesized
2,3-disubstituted-3H-Quinazolin-4-one derivatives exhibited moderate to good Anti oxidant,
Anti tumor and Anti-microbial activity. Among those Compounds C-GY, C-GU, C-TP, and C-
TY were found to be the most potent compound with Promising Anti-Oxidant activity. C-GU,
C-T were found to exhibit good Anti-Cancer activity and  Compound C-GY, C-HS, and C-
HH were found to be a good Anti Microbial agent. Further studies on its possible mechanism
and in vivo trials in experimental animals to broaden their Pharmacological assessment, may
provide a new analogue that can overcome the side effects of existing anti tumor agents . 
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